

CITATION REPORT

List of articles citing

Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review

DOI: 10.1111/ejh.13187

European Journal of Haematology, 2019, 102, 157-162.

Source: <https://exaly.com/paper-pdf/74705093/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
56	[What's new in oncodermatology?]. <i>Annales De Dermatologie Et De Venereologie</i> , 2018 , 145 Suppl 7, VIIS403-VIIS46	4.3	46
55	Antineoplastics. <i>Reactions Weekly</i> , 2019 , 1742, 33-33	0	0
54	Warm Autoimmune Hemolytic Anemia. <i>New England Journal of Medicine</i> , 2019 , 381, 647-654	59.2	53
53	Susceptibility to adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2205-2212	3.8	14
52	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019 , 94, 563-574	7.1	29
51	Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	5
50	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020 , 12,	6.6	6
49	Severe mesenteric ischemia with multiple organ failure in a patient previously treated with a humanized monoclonal antibody against programmed death receptor-1 (pembrolizumab), a case of pembrolizumab associated catastrophic antiphospholipid syndrome?. <i>SAGE Open Medical Case Reports</i> , 2020 , 8, 2050313X20972225	0.7	2
48	Difficult Cases of Autoimmune Hemolytic Anemia: A Challenge for the Internal Medicine Specialist. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
47	New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	17
46	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020 , 15, 449-466	5	37
45	Autoimmunhämolytische Anämie als seltene Nebenwirkung einer Therapie mit Pembrolizumab bei metastasiertem Melanom. <i>Tumor Diagnostik Und Therapie</i> , 2020 , 41, 463-468	0.1	0
44	Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
43	Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis. <i>BMC Cancer</i> , 2020 , 20, 527	4.8	3
42	The Changing Landscape of Autoimmune Hemolytic Anemia. <i>Frontiers in Immunology</i> , 2020 , 11, 946	8.4	36
41	Band 3 ectopic expression in colorectal cancer induces an increase in erythrocyte membrane-bound IgG and may cause immune-related anemia. <i>International Journal of Hematology</i> , 2020 , 111, 657-666	2.3	1
40	Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures. <i>Expert Review of Hematology</i> , 2020 , 13, 585-597	2.8	19

39	Atezolizumab-induced hemolytic anemia - A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 1026-1028	1.7	1
38	Bosentan-induced immune hemolytic anemia in 17 years old man. A case report. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2021 , 29, 211-215	3.9	4
37	Autoimmune Complications in Hematologic Neoplasms. <i>Cancers</i> , 2021 , 13,	6.6	15
36	Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. <i>Med</i> , 2021 , 2, 423-434	31.7	17
35	Epigenomics and immunotherapeutic advances in pediatric brain tumors. <i>Npj Precision Oncology</i> , 2021 , 5, 34	9.8	3
34	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 147, 170-181	7.5	11
33	Autoimmune hemolytic anemia during long-term administration of nivolumab for metastatic melanoma. <i>Journal of Cutaneous Immunology and Allergy</i> , 2021 , 4, 139	0.3	
32	Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021 , 12, 392-404	0.7	2
31	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. 2021 , 9,		58
30	Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	
29	Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	1
28	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. <i>Journal of Immunotherapy</i> , 2022 , 45, 13-24	5	2
27	Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report. <i>Case Reports in Oncology</i> , 2021 , 14, 1289-1294	1	0
26	Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma. <i>Yeungnam University Journal of Medicine</i> , 2021 ,	1.3	3
25	Non-Rheumatic Immune-Related Adverse Events. 2021 , 191-253		
24	Pembrolizumab-Induced Cold Agglutinin Disease. <i>American Journal of Case Reports</i> , 2020 , 21, e924283	1.3	4
23	Ceftriaxone-Induced Immune Hemolytic Anemia. <i>Cureus</i> , 2020 , 12, e8660	1.2	2
22	Hematologic complications of immune checkpoint inhibitors. <i>Blood</i> , 2021 ,	2.2	2

21	Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies.. <i>European Journal of Cancer</i> , 2022 , 162, 158-160	7.5	0
20	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.. <i>Nanotheranostics</i> , 2022 , 6, 243-255	5.6	0
19	Unintentional Dual Benefit: Improvement in Secondary Polycythemia in a Patient Receiving Chemotherapy for Metastatic Clear Cell Renal Cell Carcinoma.. <i>European Journal of Case Reports in Internal Medicine</i> , 2022 , 9, 003125	1.2	1
18	Updates in the Management of Warm Autoimmune Hemolytic Anemia.. <i>Hematology/Oncology Clinics of North America</i> , 2022 ,	3.1	
17	Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors. <i>The Korean Journal of Blood Transfusion</i> , 2021 , 32, 201-208	0.3	
16	Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review.. <i>Annals of Hematology</i> , 2022 , 101, 1-10	3	6
15	Disorders of red cells and platelets. 2022 , 316-460		
14	A Case of Lung Adenocarcinoma with Autoimmune Hemolytic Anemia Developing After Immune Checkpoint Inhibitor Treatment. <i>Japanese Journal of Lung Cancer</i> , 2021 , 61, 975-978	0.1	0
13	Immunotherapy-associated Autoimmune Hemolytic Anemia.. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 365-380	3.1	0
12	Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	1
11	Autoimmune hemolytic anemia: causes and consequences. <i>Expert Review of Clinical Immunology</i> , 1-15	5.1	1
10	Hematological Toxicity in Lung Cancer. <i>Medical Radiology</i> , 2022 ,	0.2	
9	Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system.		0
8	Hematology. 2022 , 97-117		0
7	NIVOLUMAB-INDUCED AUTOIMMUNE HAEMOLYTIC ANAEMIA. 2022 , 68, 486-490		0
6	Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective. 2022 , 550, 215920		0
5	Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database. 2022 , 14, 5030		1
4	Cytophies auto-immunes induites par les inhibiteurs de points de contrle immunitaire: ^ propos de 68 cas issus de la base nationale de pharmacovigilance. 2022 , 43, A343-A344		0

- 3 Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome: A systematic narrative appraisal of where we are now!. **2023**, 62, 103685 ○
- 2 Positive direct antiglobulin tests in cancer patients on immune checkpoint inhibitors: A case series from India. **2023**, ○
- 1 Complicați mediate imunologic ale anticorpilor monoclonali folosiți oncohematologie. **2023**, 1, 26 ○